The FDA has cleared Toshiba America Medical Systems Adaptive Iterative Dose Reduction 3D dose-reduction technology.

Roche Diagnostics Operations has initiated a Class 1 recall for its Elecsys Troponin I and Elecsys Troponin I STAT Immunoassays.

When Royal Philips Electronics announced its 2012 first quarter earnings, its Philips Healthcare unit showed a sales growth of 9 percent over the 2011 first quarter to EUR2.21 billion ($2.91 billion U.S.).

An estimated 4 to 7 percent of nuclear and molecular imaging procedures are repeated due to poor imaging, which equates to $132 million in Medicare spending on avoidable scans, according to the Government Accountability Office. The Consistency, Accuracy, Responsibility and Excellence in Medical Imaging (CARE) bill, which would establish minimum education and certification standards for personnel who perform nuclear medicine and molecular imaging procedures, could help curb these costs, according to SNM.

Denials to patients seeking critical imaging services by their insurance providers have doubled over the last four years, according to internal case management data released by the Patient Advocate Foundation (PAF). Some 90 percent of reversed denials for imaging services were covered by those health plans.

PET/CT is useful in differentiating between cardiovascular implantable electronic device infection and recent post-implant changes, and may guide appropriate therapy, according to a study in the May 1 issue of the Journal of the American College of Cardiology.

Women between the ages of 40 and 49 years who underwent routine screening mammography were diagnosed at earlier stages with smaller tumors than symptomatic women requiring diagnostic workup, according to a study published in the May issue of American Journal of Roentgenology.

Due to the National Lung Screening Trial (NLST) findings, the American Lung Association (ALA) is recommending lung cancer screening with low-dose CT scans for people who meet certain criteria, which include the following: current or former smokers (aged 55 to 74 years), with a smoking history of at least 30 pack-years and with no history of lung cancer.